Table 3.
Description of Pharmacologic Studies by Funding Source
| Funded by Industry: | Yes n=165 | % | No n=33 | % | p value |
|---|---|---|---|---|---|
| Status | 0.0016 | ||||
| Closed | |||||
| Completed | 121 | 73% | 18 | 55% | |
| Active, Not Recruiting | 3 | 2% | 2 | 6% | |
| Enrolling by Invitation | 0 | 0% | 1 | 3% | |
| Suspended | 1 | 1% | 0 | 0% | |
| Terminated | 21 | 13% | 1 | 3% | |
| Open | |||||
| Recruiting | 14 | 8% | 6 | 18% | |
| Not Yet Recruiting | 5 | 3% | 5 | 15% | |
| Duration | 0.0004 | ||||
| Less than 3 Months | 99 | 63% | 10 | 30% | |
| 3 to 6 Months | 39 | 25% | 10 | 30% | |
| 6 to 12 Months | 4 | 3% | 4 | 12% | |
| Greater than 12 Months | 15 | 10% | 9 | 27% | |
| Design | |||||
| Randomized | 139 | 85% | 32 | 97% | 0.0670 |
| Enrollment Mean (SD) | 303 | (276) | 176 | (306) | 0.0187 |
| Quality Score Mean (SD) | 2.5 | (1.0) | 2.6 | (0.8) | 0.6506 |
| Focus of study | |||||
| Novel Compounds* | 35 | 21% | 9 | 27% | 0.4457 |
| NSAIDs | 45 | 27% | 6 | 18% | 0.2769 |
| Opioids | 66 | 40% | 3 | 9% | 0.0007 |
| Outcomes | |||||
| VAS | 129 | 78% | 19 | 58% | 0.0131 |
| WOMAC | 98 | 59% | 11 | 33% | 0.0061 |
| KOOS | 2 | 1% | 5 | 15% | <0.0001 |
| QOL | 47 | 28% | 15 | 45% | 0.0556 |
*
Includes novel inhibitors, biologics, and centrally- or peripherally-acting compounds.